2 For all patients with nonsquamous NSCLC and with tissue evaluable for mutational analysis (n = 313), the FoundationOne CDx™ assay was used to identify mutant (mut) or wild-type (wt) KRAS and STK11 genes. The study assessed overall survival (OS), progression-free survival (PFS), and objective response rate. Patients with nonsquamous NSCLC in the chemotherapy-alone arm could receive pemetrexed maintenance. Patients were stratified by tumor PD-L1 expression level, sex, and histology. 2 The patients were randomized 1:1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks plus 2 cycles of chemotherapy (n = 361) or 4 cycles of platinum-based chemotherapy alone (n = 358). 2ĬheckMate 9LA enrolled patients with stage IV or recurrent NSCLC with no known sensitizing EGFR/ALK alterations and an Eastern Cooperative Oncology Group performance status of 0 or 1. 1 In a late-breaking presentation at the 2022 American Society of Clinical Oncology Annual Meeting, Paz-Ares and colleagues reported updated 3-year efficacy and safety data, and the results of exploratory biomarker analyses. The CheckMate 9LA trial demonstrated that treatment of patients with metastatic non–small-cell lung cancer (NSCLC) with nivolumab plus ipilimumab combined with 2 cycles of chemotherapy improved survival benefits compared with treatment of 4 cycles of chemotherapy alone. Response to Vidutolimod in Patients with Anti–įirst-Line Nivolumab plus Ipilimumab in Combination with Chemotherapy versus Chemotherapy Alone in Patients with Metastatic NSCLC: 3-Year Update from CheckMate 9LA The 3-year extended follow-up of CheckMate 9LA demonstrated that first-line nivolumab plus ipilimumab in combination with limited chemotherapy resulted in long-term, durable clinical benefit compared with chemotherapy alone in patients with metastatic NSCLC, regardless of PD-L1 mutation status. Novel Transcriptional Signatures Associated with.Healthcare Utilization in Patients with Advanced Impact of Performance Status on Response and.Time-Dependent Efficacy of Nivolumab in.Investigation of Acquired Resistance Biomarkers.Response to PD-1 Inhibition in Patients with Radiology, Pathology, and Genomics to Predict Lung Cancer Treatment Selection Based on a.Circulating Tumor DNA–Guided Therapy of.First-Line Anti–PD-(L)1 Therapy with or without.With Chemotherapy in Patients with PD-L1–High Anti–PD-(L)-1 Monotherapy versus Combination.Inhibitors with or without Chemotherapy in Real-World Effectiveness of Immune Checkpoint.CTLA-4 Single-Nucleotide Polymorphism IsĪssociated with High Response to Anti–PD-1/.ATM Mutations in NSCLC Define Patients with.Nivolumab plus Ipilimumab versus Chemotherapy Five-Year Survival Outcomes of First-Line.A Phase 3 Study of First-Line SugemalimabĬhemotherapy for Patients with Metastatic.Without EGFR/ALK Mutations: CHOICE-01 Phase Toripalimab versus Placebo in Combination withįirst-Line Chemotherapy for Advanced NSCLC.Recurrent NSCLC: Results from the Phase 2/3 Patients with Previously Treated Advanced or Nivolumab with or without Docetaxel for.With Novel Agents for Resectable, Early-Stage Neoadjuvant Durvalumab Alone or Combined.Neoadjuvant Nivolumab and Platinum-Doublet.Ipilimumab in Patients with Squamous-Cell Lung Guided Therapy with Nivolumab with or without Analysis of Serum Protein Levels for Biomarker.MEDI5752, a Novel PD-1/CTLA-4 BispecificĬheckpoint Inhibitor for Advanced Solid Tumors:.Camrelizumab Combined with Apatinib andĪlbumin Paclitaxel in Advanced Nonsquamous.First-Line Treatment of Metastatic NSCLC withĭurvalumab with or without Tremelimumab in.Immune Checkpoint Inhibitors: The PIONeeR Trial Resistance Biomarkers to PD-1/PD-L1–Targeted.First-Line Nivolumab plus Ipilimumab inĬhemotherapy Alone in Patients with Metastatic.We hope that the information reviewed here can be applied to clinical practice and offers valuable insights into the important progress that is being made in the care of patients with NSCLC. In this print supplement, we will summarize pivotal clinical data that were presented on immune checkpoint inhibitor therapy of NSCLC at both of these key meetings.Ī total of 25 data presentations from AACR 2022 and ASCO 2022 are summarized in this resource. We are pleased to provide highlights of important and potentially practice-changing developments in immunotherapy of non–small-cell lung cancer (NSCLC) presented at the 2022 annual meetings of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |